Breaking News

ICON Adds COO Role, Names Team Leaders

By Kristin Brooks | January 10, 2014

Cutler to oversee all ops, Murphy and Miskel take on Clinical and Lab units

Dr. Steve Cutler has been appointed to the newly created position of chief operating officer at ICON plc. Dr. Cutler will be responsible for the company’s operational units, covering Early Phase, Clinical, Laboratories, Commercialization and Outcomes and DOCS FSP & resourcing. Dr. Cutler will also be responsible for ICON’s sales and marketing and strategic alliance teams. He joined the company in November 2011 as group president, Clinical Research Services. 
Within Dr. Cutler’s team, Dr. Nuala Murphy has been appointed president, ICON Clinical Services, and Jim Miskel has been appointed executive vice president and general manager, ICON Laboratory Services. 
Dr. Murphy will oversee ICON’s global clinical services, including clinical and data operations, study start-up, project management, clinical risk management, technology services and clinical scientific operations. Dr. Murphy joined ICON in 2012 as executive vice president, Global Clinical Operations and Data Management.
Mr. Miskel will lead ICON’s newly combined Central and Bioanalytical laboratories group. He joined the company in November 2013 and brings extensive lab and pharma industry experience.
Ciaran Murray, chief executive officer of ICON, said, “We continually review our structure to ensure that as the market evolves, our organization can continue to provide customers with innovative and integrated solutions across our various service lines and business units. Bringing all operational units under Steve’s leadership will allow us to further enhance the support we can offer to our customers’ development programs. I would like to congratulate Steve, Nuala and Jim on their new roles and wish them every success in the future.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks